POM-V
Prescription Required
Companion Animal
Refordog 100 mg/500 mg Spot-on Solution for Dogs over 4 kg up to 10 kg
Active ingredients: Imidacloprid, Permethrin (Cis:Trans 40:60)
Form
Spot-on
Species
Dogs
Manufacturer
Vetpharma Animal Health, S.L
VMD MA No.
32509/3001
What it's used for
against all the following parasite species is required at the same time. For the treatment and prevention of flea (Ctenocephalides canis, ) infestation and...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Imidacloprid + Permethrin (C...
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Refordog 100 mg/500 mg Spot-on Solution for Dogs over 4 kg up to 10 kg — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
against all the following parasite species is required at the same time.
For the treatment and prevention of flea (Ctenocephalides canis, )
infestation and for the treatment of biting lice (Trichodectes canis).
Fleas on dogs are killed within one day following treatment. One treatment prevents
further flea infestation for four weeks. The veterinary medicinal product can be used as
part of a treatment strategy for flea allergy dermatitis (FAD).
AN: 01456/2025 & 03248/2025
The veterinary medicinal product has persistent acaricidal and repellent efficacy against
tick infestations (Rhipicephalus sanguineus and for four weeks, and
Dermacentor reticulatus for three weeks).
By repelling and killing the tick vector , the veterinary medicinal
product reduces the likelihood of transmission of the pathogen , thereby
reducing the risk of canine ehrlichiosis. The reduction in risk has been shown in studies
to commence from 3 days following application of the veterinary medicinal product and to
persist for 4 weeks.
Ticks already on the dog may not be killed within two days after treatment and may remain
attached and visible. Therefore, the removal of ticks already on the dog at the time of
treatment is recommended, in order to prevent them from attaching and having a blood
meal.
One treatment provides repellent (anti-feeding) activity against sand flies (Phlebotomus
papatasi for two weeks and for three weeks), against
mosquitoes (Aedes aegypti for two weeks and for four weeks) and against
stable flies (Stomoxys calcitrans) for four weeks.
Reduction of the risk of infection with via transmission by sandflies
(Phlebotomus perniciosus) for up to 3 weeks. The effect is indirect due to the veterinary
medicinal product's activity against the vector.
For the treatment and prevention of flea (Ctenocephalides canis, )
infestation and for the treatment of biting lice (Trichodectes canis).
Fleas on dogs are killed within one day following treatment. One treatment prevents
further flea infestation for four weeks. The veterinary medicinal product can be used as
part of a treatment strategy for flea allergy dermatitis (FAD).
AN: 01456/2025 & 03248/2025
The veterinary medicinal product has persistent acaricidal and repellent efficacy against
tick infestations (Rhipicephalus sanguineus and for four weeks, and
Dermacentor reticulatus for three weeks).
By repelling and killing the tick vector , the veterinary medicinal
product reduces the likelihood of transmission of the pathogen , thereby
reducing the risk of canine ehrlichiosis. The reduction in risk has been shown in studies
to commence from 3 days following application of the veterinary medicinal product and to
persist for 4 weeks.
Ticks already on the dog may not be killed within two days after treatment and may remain
attached and visible. Therefore, the removal of ticks already on the dog at the time of
treatment is recommended, in order to prevent them from attaching and having a blood
meal.
One treatment provides repellent (anti-feeding) activity against sand flies (Phlebotomus
papatasi for two weeks and for three weeks), against
mosquitoes (Aedes aegypti for two weeks and for four weeks) and against
stable flies (Stomoxys calcitrans) for four weeks.
Reduction of the risk of infection with via transmission by sandflies
(Phlebotomus perniciosus) for up to 3 weeks. The effect is indirect due to the veterinary
medicinal product's activity against the vector.
weighed accurately prior to treatment.
Underdosing could result in ineffective use and may favour resistance development.
The recommended minimum dose is:
10 mg/kg body weight (bw) imidacloprid and 50 mg/kg body weight (bw) permethrin.
AN: 01456/2025 & 03248/2025
Dosing Scheme for the veterinary medicinal product:
Dogs (kg body
weight)
Volume
(ml)
Content of
imidacloprid /
permethrin
Imidacloprid
(mg/kg body
weight)
Permethrin
(mg/kg body
weight)
> 1.5 kg 4 kg0.4 ml40 mg/200 mg10 - 2650 - 133> 4 kg 10 kg1.0 ml100 mg/500 mg10 - 2550 - 125
> 10 kg 25 kg2.5 ml
250 mg/1250
mg
10 - 2550 - 125> 25 kg 40 kg4.0 ml
400 mg/2000
mg
10 - 1650 - 80> 40 kg 60 kg6.0 ml
600 mg/3000
mg
10 - 1550 - 75
For dogs > 60 kg the appropriate combination with other sized pipettes should be used.
In case of biting louse infestation, a further veterinary examination 30 days after
treatment is recommended as some animals may require a second treatment.
To protect a dog over the whole sand fly season, treatment should be compliantly
continued throughout.
For infestations with fleas, ticks, mosquitos and stable flies, the need for and frequency
of re-treatment(s) should be based on professional advice and should take into account
the local epidemiological situation and the animal’s lifestyle.
Method for administration
Remove one pipette from the package. Hold applicator pipette in an upright position for
opening it.
The cap should be rotated clockwise or counter clockwise one full turn. The cap will stay
on the pipette; it is not possible to remove it. The pipette is open and ready for application.
The entire content of the pipette has to be applied to the animal’s skin.
Veterinary medicinal product for dogs over 1,5 kg up to 4 kg and veterinary medicinal
product for dogs over 4 kg up to 10 kg:
With the dog standing still, part the coat between the shoulder blades until the skin is
visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty
the contents directly onto the skin.
AN: 01456/2025 & 03248/2025
Veterinary medicinal product for dogs over 10 kg up to 25 kg, veterinary medicinal
product for dogs over 25 kg up to 40 kg, and veterinary medicinal product for dogs over
40 kg up to 60 kg:
With the dog standing still, the entire contents of the pipette should be applied evenly to
four spots on the top of the back from the shoulder to the base of the tail. At each spot,
part the hair until the skin is visible. Place the tip of the pipette on the skin and gently
squeeze to expel a portion of the solution on the skin. Do not apply an excessive
amount of solution at any one spot that could cause some of the solution to run off the
side of the dog.
Underdosing could result in ineffective use and may favour resistance development.
The recommended minimum dose is:
10 mg/kg body weight (bw) imidacloprid and 50 mg/kg body weight (bw) permethrin.
AN: 01456/2025 & 03248/2025
Dosing Scheme for the veterinary medicinal product:
Dogs (kg body
weight)
Volume
(ml)
Content of
imidacloprid /
permethrin
Imidacloprid
(mg/kg body
weight)
Permethrin
(mg/kg body
weight)
> 1.5 kg 4 kg0.4 ml40 mg/200 mg10 - 2650 - 133> 4 kg 10 kg1.0 ml100 mg/500 mg10 - 2550 - 125
> 10 kg 25 kg2.5 ml
250 mg/1250
mg
10 - 2550 - 125> 25 kg 40 kg4.0 ml
400 mg/2000
mg
10 - 1650 - 80> 40 kg 60 kg6.0 ml
600 mg/3000
mg
10 - 1550 - 75
For dogs > 60 kg the appropriate combination with other sized pipettes should be used.
In case of biting louse infestation, a further veterinary examination 30 days after
treatment is recommended as some animals may require a second treatment.
To protect a dog over the whole sand fly season, treatment should be compliantly
continued throughout.
For infestations with fleas, ticks, mosquitos and stable flies, the need for and frequency
of re-treatment(s) should be based on professional advice and should take into account
the local epidemiological situation and the animal’s lifestyle.
Method for administration
Remove one pipette from the package. Hold applicator pipette in an upright position for
opening it.
The cap should be rotated clockwise or counter clockwise one full turn. The cap will stay
on the pipette; it is not possible to remove it. The pipette is open and ready for application.
The entire content of the pipette has to be applied to the animal’s skin.
Veterinary medicinal product for dogs over 1,5 kg up to 4 kg and veterinary medicinal
product for dogs over 4 kg up to 10 kg:
With the dog standing still, part the coat between the shoulder blades until the skin is
visible. Place the tip of the pipette on the skin and squeeze firmly several times to empty
the contents directly onto the skin.
AN: 01456/2025 & 03248/2025
Veterinary medicinal product for dogs over 10 kg up to 25 kg, veterinary medicinal
product for dogs over 25 kg up to 40 kg, and veterinary medicinal product for dogs over
40 kg up to 60 kg:
With the dog standing still, the entire contents of the pipette should be applied evenly to
four spots on the top of the back from the shoulder to the base of the tail. At each spot,
part the hair until the skin is visible. Place the tip of the pipette on the skin and gently
squeeze to expel a portion of the solution on the skin. Do not apply an excessive
amount of solution at any one spot that could cause some of the solution to run off the
side of the dog.
In the absence of available data, the veterinary medicinal product should not be used on
puppies of less than 7 weeks of age or dogs of 1.5 kg of weight or less.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
Do not use on cats. (Refer to section 3.5 – Other precautions).
puppies of less than 7 weeks of age or dogs of 1.5 kg of weight or less.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
Do not use on cats. (Refer to section 3.5 – Other precautions).
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Application site itching, application site hair change
(e.g. greasy fur).
Vomiting.
Rare
(1 to 10 animals / 10,000
animals treated):
Application site erythema, application site
inflammation, application site hair loss.
Diarrhoea.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Increased skin sensitivity (scratching, rubbing).
1,2
Lethargy.
Agitation
1,2,3
, restlessness
1,2,3
, whining
1,2,3
,
rolling.
1,2,3
Hypersalivation
1,2,3
, decreased appetite.
1,2,3
Neurological disorder (e.g. abnormal movement,
twitching).
1,2,3
transient
self-resolving
in dogs susceptible to permethrin
Poisoning following inadvertent oral uptake in dogs is unlikely but may occur in very rare
cases. In this event, neurological disorders such as tremor and lethargy can occur.
Treatment should be symptomatic. There is no known specific antidote.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
(1 to 10 animals / 1,000 animals
treated):
Application site itching, application site hair change
(e.g. greasy fur).
Vomiting.
Rare
(1 to 10 animals / 10,000
animals treated):
Application site erythema, application site
inflammation, application site hair loss.
Diarrhoea.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Increased skin sensitivity (scratching, rubbing).
1,2
Lethargy.
Agitation
1,2,3
, restlessness
1,2,3
, whining
1,2,3
,
rolling.
1,2,3
Hypersalivation
1,2,3
, decreased appetite.
1,2,3
Neurological disorder (e.g. abnormal movement,
twitching).
1,2,3
transient
self-resolving
in dogs susceptible to permethrin
Poisoning following inadvertent oral uptake in dogs is unlikely but may occur in very rare
cases. In this event, neurological disorders such as tremor and lethargy can occur.
Treatment should be symptomatic. There is no known specific antidote.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Unnecessary use of antiparasitics or use deviating from the instructions given in the
SPC may increase the resistance selection pressure and lead to reduced efficacy. The
decision to use the veterinary medicinal product should be based on confirmation of the
parasitic species and burden, or of the risk of infestation based on its epidemiological
features for each animal.
Resistance to permethrin has been reported in fleas, ticks (Rhipicephalus sanguineus),
in stable flies (Stomoxys calcitrans), mosquitoes (Culex pipiens, Aedes aegypti) and
sandflies (P. papatasi).
The use of this veterinary medicinal product should take into account local information
about susceptibility of the target parasites, where available. It is recommended to further
investigate cases of suspected resistance, using an appropriate diagnostic method.
Confirmed resistance should be reported to the marketing authorisation holder or to the
competent authorities.
In the absence of risk of co-infection with fleas, ticks and/or sandflies, a narrow
spectrum product should be used.
AN: 01456/2025 & 03248/2025
There may be an attachment of single ticks or bites by single sand flies or mosquitoes.
For this reason, a transmission of infectious diseases by these parasites cannot be
completely excluded if conditions are unfavourable.
It is recommended to apply the treatment at least 3 days before expected exposure to
canis, studies have demonstrated a reduced risk of canine
ehrlichiosis in dogs exposed to ticks infected with from
3 days following application of the veterinary medicinal product and to persist for 4 weeks.
Immediate protection against sandflies bites is not documented. Treated dogs for the
reduction of the risk of infection with via transmission by sandflies
P. Perniciosus
the initial treatment application.
The possibility that other animals in the same household can be a source of re-infection
with fleas, ticks or biting lice should be considered, and these should be treated as
necessary with an appropriate product. To aid further in reducing environmental
challenge, the additional use of a suitable environmental treatment against adult fleas
and their developmental stages is recommended.
The veterinary medicinal product remains effective if the animal becomes wet. However,
prolonged, intense exposure to water should be avoided. In cases of frequent water
exposure, the persistent efficacy may be reduced. In these cases, do not retreat more
frequently than once weekly. If a dog requires a shampoo, it should be administered
before applying the veterinary medicinal product or at least 2 weeks after application, to
optimise efficacy of the veterinary medicinal product.
Special precautions for safe use in the target species:
Care should be taken to avoid the content of the pipette coming into contact with the
eyes or mouth of the recipient dogs.
Care should be taken to administer the veterinary medicinal product correctly as
described under section 3.9. In particular, oral uptake due to the licking of the
application site by treated or in-contact animals should be avoided.
Consult your veterinary surgeon before using the veterinary medicinal product on sick
and debilitated dogs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This veterinary medicinal product contains butylhydroxytoluene which may cause local
skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.
The predominant clinical symptoms that in extremely rare case may be shown are
transient sensory irritations of the skin like tingling, burning sensation or numbness.
Avoid contact between the veterinary medicinal product and skin, eyes or mouth.
Do not eat, drink or smoke during application. Do not ingest.
AN: 01456/2025 & 03248/2025
Wash hands thoroughly after use.
In order to prevent children from getting access to pipettes, keep the pipette in the original
packaging until ready for use and dispose of used pipettes immediately.
In case of accidental spillage onto skin, wash off immediately with soap and water.
People with known hypersensitivity to permethrin should avoid contact with the veterinary
medicinal product.
If the veterinary medicinal product gets accidentally into the eyes, they should be
thoroughly flushed with water. If skin or if eye irritation persists, obtain medical attention
immediately and show the package insert to the physician.
In case of accidental ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.
Treated dogs must not be handled especially by children for at least 12 hours after
application of the veterinary medicinal product. It is therefore recommended to treat the
dogs e.g. in the evening. Recently treated dogs should not be allowed to sleep together
with their owner, especially children.
Special precautions for the protection of the environment:
As the veterinary medicinal product is dangerous for aquatic organisms, treated dogs
must not under any circumstances be allowed into any type of surface water for at least
48 hours after treatment.
Other precautions:
Do not use on cats.
This veterinary medicinal product is extremely poisonous to cats and could be fatal due
to the unique physiology of cats which is unable to metabolise certain compounds
including permethrin. To prevent cats from being accidentally exposed to the veterinary
medicinal product, keep treated dogs away from cats after treatment until the
application site is dry. It is important to ensure that cats do not groom the site of
application on a dog, which has been treated with this veterinary medicinal product.
Seek veterinary advice immediately if this occurs.
The solvent in the spot-on veterinary medicinal product may stain certain materials
including leather, fabrics, plastics and finished surfaces. Allow the application site to dry
before permitting contact with such materials.
AN: 01456/2025 & 03248/2025
SPC may increase the resistance selection pressure and lead to reduced efficacy. The
decision to use the veterinary medicinal product should be based on confirmation of the
parasitic species and burden, or of the risk of infestation based on its epidemiological
features for each animal.
Resistance to permethrin has been reported in fleas, ticks (Rhipicephalus sanguineus),
in stable flies (Stomoxys calcitrans), mosquitoes (Culex pipiens, Aedes aegypti) and
sandflies (P. papatasi).
The use of this veterinary medicinal product should take into account local information
about susceptibility of the target parasites, where available. It is recommended to further
investigate cases of suspected resistance, using an appropriate diagnostic method.
Confirmed resistance should be reported to the marketing authorisation holder or to the
competent authorities.
In the absence of risk of co-infection with fleas, ticks and/or sandflies, a narrow
spectrum product should be used.
AN: 01456/2025 & 03248/2025
There may be an attachment of single ticks or bites by single sand flies or mosquitoes.
For this reason, a transmission of infectious diseases by these parasites cannot be
completely excluded if conditions are unfavourable.
It is recommended to apply the treatment at least 3 days before expected exposure to
canis, studies have demonstrated a reduced risk of canine
ehrlichiosis in dogs exposed to ticks infected with from
3 days following application of the veterinary medicinal product and to persist for 4 weeks.
Immediate protection against sandflies bites is not documented. Treated dogs for the
reduction of the risk of infection with via transmission by sandflies
P. Perniciosus
the initial treatment application.
The possibility that other animals in the same household can be a source of re-infection
with fleas, ticks or biting lice should be considered, and these should be treated as
necessary with an appropriate product. To aid further in reducing environmental
challenge, the additional use of a suitable environmental treatment against adult fleas
and their developmental stages is recommended.
The veterinary medicinal product remains effective if the animal becomes wet. However,
prolonged, intense exposure to water should be avoided. In cases of frequent water
exposure, the persistent efficacy may be reduced. In these cases, do not retreat more
frequently than once weekly. If a dog requires a shampoo, it should be administered
before applying the veterinary medicinal product or at least 2 weeks after application, to
optimise efficacy of the veterinary medicinal product.
Special precautions for safe use in the target species:
Care should be taken to avoid the content of the pipette coming into contact with the
eyes or mouth of the recipient dogs.
Care should be taken to administer the veterinary medicinal product correctly as
described under section 3.9. In particular, oral uptake due to the licking of the
application site by treated or in-contact animals should be avoided.
Consult your veterinary surgeon before using the veterinary medicinal product on sick
and debilitated dogs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This veterinary medicinal product contains butylhydroxytoluene which may cause local
skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.
The predominant clinical symptoms that in extremely rare case may be shown are
transient sensory irritations of the skin like tingling, burning sensation or numbness.
Avoid contact between the veterinary medicinal product and skin, eyes or mouth.
Do not eat, drink or smoke during application. Do not ingest.
AN: 01456/2025 & 03248/2025
Wash hands thoroughly after use.
In order to prevent children from getting access to pipettes, keep the pipette in the original
packaging until ready for use and dispose of used pipettes immediately.
In case of accidental spillage onto skin, wash off immediately with soap and water.
People with known hypersensitivity to permethrin should avoid contact with the veterinary
medicinal product.
If the veterinary medicinal product gets accidentally into the eyes, they should be
thoroughly flushed with water. If skin or if eye irritation persists, obtain medical attention
immediately and show the package insert to the physician.
In case of accidental ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.
Treated dogs must not be handled especially by children for at least 12 hours after
application of the veterinary medicinal product. It is therefore recommended to treat the
dogs e.g. in the evening. Recently treated dogs should not be allowed to sleep together
with their owner, especially children.
Special precautions for the protection of the environment:
As the veterinary medicinal product is dangerous for aquatic organisms, treated dogs
must not under any circumstances be allowed into any type of surface water for at least
48 hours after treatment.
Other precautions:
Do not use on cats.
This veterinary medicinal product is extremely poisonous to cats and could be fatal due
to the unique physiology of cats which is unable to metabolise certain compounds
including permethrin. To prevent cats from being accidentally exposed to the veterinary
medicinal product, keep treated dogs away from cats after treatment until the
application site is dry. It is important to ensure that cats do not groom the site of
application on a dog, which has been treated with this veterinary medicinal product.
Seek veterinary advice immediately if this occurs.
The solvent in the spot-on veterinary medicinal product may stain certain materials
including leather, fabrics, plastics and finished surfaces. Allow the application site to dry
before permitting contact with such materials.
AN: 01456/2025 & 03248/2025
None known.
This veterinary medicinal product does not require any special storage conditions.
Not applicable.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Imidacloprid
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSElanco GmbH
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSElanco GmbH
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
Flea & Tick Treatments for Dogs
Vet-strength flea and tick treatments at pharmacy prices. Frontline, Advocate, Bravecto, Nexgard and more.
From £8.99
Shop now
Pharmacy2U
Pet Flea Treatments at Pharmacy2U
Frontline, Advantage and own-brand flea treatments at pharmacy prices. Trusted UK pharmacy since 1999.
From £7.99
Shop now
VetBox
VetBox Flea & Worm Protection for Dogs
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
From £9.99/month
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in flea-tick
Related Medications
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.